QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed ... more
QIAGEN Enables Efforts to Eradicate Costly Cattle Disease
Collaboration with Swiss laboratory Microsynth AG pioneers nucleic acid-based primary screening for Bovine Viral Diarrhea
QIAGEN N.V. announced that it has been awarded a contract by the Swiss life science company Microsynth AG to supply the molecular cador BVDV assays for detection of viruses causing Bovine Viral Diarrhea (BVD), one of the most widespread and costly infectious cattle diseases. The multi-year agreement is part of the Swiss national BVD eradication program in which over one million cows are to be screened to identify and contain infectious animals. QIAGEN and Mircosynth are pioneering the use of nucleic acid based tests for primary screening in a BVD eradication program. Currently, over 50 per cent of the Swiss cattle population are believed to be exposed to the BVD virus (BVDV), causing significant economic cost to the livestock industry as the infection can lead to a dramatic loss in weight.
Microsynth AG is one of a few laboratories accredited by the Swiss government to perform tests for BVDV. The laboratory has signed exclusive contracts with several Swiss cantons accounting for about one-third of the Swiss cattle population to perform both initial tests based upon tissue samples and follow-up tests to verify positive results using blood samples. The main phase of the program will last three months and is scheduled to start in October 2008. Unlike in other countries, the Swiss program is designed to test every single animal, thus putting highest demands on test methodology and logistics.
Microsynth is pioneering the implementation of molecular testing for primary screening of BVDV, which provides several unique benefits compared to traditional testing methods aiming at viral antibodies or antigens. QIAGEN's cador BVDV assay is based on the polymerase chain reaction (PCR) technology and can detect even tiny traces of viral RNA from a wide range of biological samples. Unlike traditional methods, PCR enables the direct detection of the pathogen itself independent of the immune status of an animal, which is also important for the screening of newborn calves. The assay enables the testing of pooled samples and is suited for high-throughput settings. It has already proven successful by Microsynth in screening 50,000 samples from young animals before their first summer pasture. During the main phase of the eradication program, Microsynth expects to process as many as 350,000 biological samples in just three months. The agreement also covers continuing screening of newborn calves through October 2009.
- Life Sciences
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN. The amendment provides for an increase from the original of ... more
QIAGEN announced that it has obtained derogation in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2. At the same time, ... more
Microsynth Products & Services: Oligonucleotide Synthesis, Sanger Sequencing, Next Generation Sequencing, DNA/RNA Isolation, qPCR, ddPCR, Genotyping … more
- 1analytica 2020 with very good results in the digital format
- 2Researchers find the favourite food of an enigmatic intestinal bacterium
- 3Spread of a novel SARS-CoV-2 variant across Europe in summer 2020
- 4How deadly parasites ‘glide’ into human cells
- 5analytica 2020: The world’s largest virtual trade fair for analysis, laboratory technology and biotechnology
- 6New cancer diagnostics: A glimpse into the tumor in 3D
- 7Midbrain organoids for automated chemical screening and disease research
- 8Artificial Intelligence has learned to estimate oil viscosity
- 9Nanopatterns of proteins detected by cryo-electron microscopy
- 10World record resolution in cryo-electron microscopy
- Merck Collaborates with Mammoth Biosciences to Scale New SARS-CoV-2 Test
- InnoME and Etaluma Announce Imaging Strategic Partnership
- DKSH extends partnership with Bruker in China
- Merck and Rigaku Form Partnership to Develop Novel Molecular Structure Analy ...
- DKSH and Bruker AXS strengthen partnership in China